PROTACs: A novel strategy for cancer drug discovery and development
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PROTACs: A novel strategy for cancer drug discovery and development
Authors
Keywords
-
Journal
MedComm
Volume 4, Issue 3, Pages -
Publisher
Wiley
Online
2023-05-30
DOI
10.1002/mco2.290
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach
- (2023) Qiuxia Chen et al. ACS Chemical Biology
- CRISPR Screen Reveals BRD2/4 Molecular Glue-like Degrader via Recruitment of DCAF16
- (2023) Andrea G. Shergalis et al. ACS Chemical Biology
- Targeted Degradation of PD‐L1 and Activation of the STING Pathway by Carbon‐Dot‐Based PROTACs for Cancer Immunotherapy
- (2023) Wen Su et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Cereblon neo-substrate binding mimics the recognition of the cyclic imide degron
- (2023) Christopher Heim et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Design, synthesis and biological evaluation of KRASG12C-PROTACs
- (2023) Xiaoyi Zhang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Janus kinase/signal transducers and activator of transcription (JAK/STAT) and its role in Lung inflammatory disease
- (2023) Manish Purohit et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Progress of small molecules for targeted protein degradation: PROTACs and other technologies
- (2023) Hong‐Yi Zhao et al. DRUG DEVELOPMENT RESEARCH
- Discovery of the GSH responsive “Y-PROTACs” targeting ALK and CDK4/6 as a potential treatment for cancer
- (2023) Shirui Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Targeting the NRF2/KEAP1 pathway in cervical and endometrial cancers
- (2023) Giovanni Tossetta et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Transcriptome- and metabolome-based candidate mechanism of BCR-ABL-independent resistance to olverembatinib in Philadelphia chromosome–positive acute lymphoblastic leukemia
- (2023) Zhao Yin et al. FUNCTIONAL & INTEGRATIVE GENOMICS
- MEK Is a Potential Indirect Target in Subtypes of Head and Neck Cancers
- (2023) Bianka Gurbi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Roles of Estrogen, Estrogen Receptors, and Estrogen-Related Receptors in Skeletal Muscle: Regulation of Mitochondrial Function
- (2023) Kenta Yoh et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis
- (2023) Koichi Ando et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy
- (2023) Yihong He et al. JOURNAL OF CONTROLLED RELEASE
- Protein degradation: expanding the toolbox to restrain cancer drug resistance
- (2023) Hui Ming et al. Journal of Hematology & Oncology
- Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia
- (2023) Atsunori Kaneshige et al. Journal of Medicinal Chemistry
- Inducible Degradation of Oncogenic Nucleolin Using an Aptamer-Based PROTAC
- (2023) Miao Chen et al. Journal of Medicinal Chemistry
- The CRL4DCAF6 E3 ligase ubiquitinates CtBP1/2 to induce apoptotic signalling and promote intervertebral disc degeneration
- (2023) Changchun Tseng et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Exploring PROTAC Cooperativity with Coarse-Grained Alchemical Methods
- (2023) Huanghao Mai et al. Journal of Physical Chemistry B
- Engineered PROTAC-CID Systems for Mammalian Inducible Gene Regulation
- (2023) Dacheng Ma et al. Journal of the American Chemical Society
- A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo
- (2023) Atsunori Kaneshige et al. Nature Chemical Biology
- Anticancer or carcinogenic? The role of estrogen receptor β in breast cancer progression
- (2023) Kang Shen et al. PHARMACOLOGY & THERAPEUTICS
- Inhibitors of Keap1-Nrf2 protein-protein interaction reduce estrogen responsive gene expression and oxidative stress in estrogen receptor-positive breast cancer
- (2023) Tingying Xie et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Discovery of a Novel Series of Imidazopyrazine Derivatives as Potent SHP2 Allosteric Inhibitors
- (2023) Esther Torrente et al. ACS Medicinal Chemistry Letters
- Androgen receptor-dependent regulation of metabolism in high grade bladder cancer cells
- (2023) Kimberley D. Katleba et al. Scientific Reports
- Palmitoylation and PDE6δ regulate membrane-compartment-specific substrate ubiquitylation and degradation
- (2023) David Liang et al. Cell Reports
- Characterization of Infiltrating Immune Cells and Secretory or Membrane-Associated Proteins in KRAS Lung Adenocarcinoma
- (2023) Yunyi Bian et al. Journal of Immunology Research
- STAT5b: A master regulator of key biological pathways
- (2023) Madison R. Smith et al. Frontiers in Immunology
- Assessment of Retinal Pigment Epithelium Alterations and Chorioretinal Vascular Network Analyses in Patients under Treatment with BRAF/MEK Inhibitor for Different Malignancies: A Pilot Study
- (2023) Giuseppe Fasolino et al. Journal of Clinical Medicine
- The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity
- (2023) Geng Liu et al. Communications Biology
- Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice
- (2023) Sajid Khan et al. Cell Death Discovery
- DTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study
- (2023) Scott F. Huntington et al. AMERICAN JOURNAL OF HEMATOLOGY
- Neuroprotective effect of a Keap1-Nrf2 Protein-Protein Inter-action inhibitor on cerebral Ischemia/Reperfusion injury
- (2023) Zengxin Qi et al. BIOORGANIC CHEMISTRY
- PROTACs: Promising approach for anticancer therapy
- (2023) Simran Deep Kaur et al. CANCER LETTERS
- MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors
- (2023) Dana C. Borcherding et al. CLINICAL CANCER RESEARCH
- STAT3 as a therapeutic target in the metformin-related treatment
- (2023) Weiran Zhang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Emerging Evidence on Membrane Estrogen Receptors as Novel Therapeutic Targets for Central Nervous System Pathologies
- (2023) Agnieszka Wnuk et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer
- (2023) Josep Tabernero et al. ONCOLOGIST
- Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors
- (2023) Yongkang Bai et al. NEOPLASIA
- ALK-positive lung cancer: a moving target
- (2023) Jaime L. Schneider et al. Nature Cancer
- Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC
- (2022) Fang Yang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate
- (2022) Philip G. Humphreys et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications
- (2022) Nathaniel J. Henning et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Strategies for designing proteolysis targeting chimaeras (PROTACs)
- (2022) Shipeng He et al. MEDICINAL RESEARCH REVIEWS
- PROTAC targeted protein degraders: the past is prologue
- (2022) Miklós Békés et al. NATURE REVIEWS DRUG DISCOVERY
- Development of Potent and Selective Janus Kinase 2/3 Directing PG–PROTACs
- (2022) Lisa J. Alcock et al. ACS Medicinal Chemistry Letters
- Chaperone‐mediated autophagy degrades Keap1 and promotes Nrf2‐mediated antioxidative response
- (2022) Lin Zhu et al. AGING CELL
- Strategies to Reduce the On‐Target Platelet Toxicity of Bcl‐x L Inhibitors: PROTACs, SNIPERs and Prodrug‐Based Approaches
- (2022) Arvind Negi et al. CHEMBIOCHEM
- Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents
- (2022) Chao Wang et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Hijacking Methyl Reader Proteins for Nuclear-Specific Protein Degradation
- (2022) Dhanusha A. Nalawansha et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- HJM-561, a potent, selective and orally bioavailable EGFR PROTAC that overcomes osimertinib-resistant EGFR triple mutations
- (2022) Yong Du et al. MOLECULAR CANCER THERAPEUTICS
- Modulating the Ubiquitin–Proteasome System: A Therapeutic Strategy for Autoimmune Diseases
- (2022) Dhananjay Yadav et al. Cells
- Ubiquitin-Proteasome System–Regulated Protein Degradation in Spermatogenesis
- (2022) Yi Xiong et al. Cells
- An update of Nrf2 activators and inhibitors in cancer prevention/promotion
- (2022) Farhad Pouremamali et al. Cell Communication and Signaling
- Recent Progress in Histone deacetylase (HDAC) 1 Inhibitors as Anticancer Agent.
- (2022) Preeti Patel et al. CURRENT CANCER DRUG TARGETS
- Next-generation Bruton’s tyrosine kinase (BTK) inhibitors potentially targeting BTK C481S mutation- Recent developments and Perspectives.
- (2022) Debasis Das et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Androgen receptor pathway inhibitor combination in prostate cancer
- (2022) Kelvin Yan Nature Reviews Urology
- PROTAC technology as a novel tool to identify the target of lathyrane diterpenoids
- (2022) Yanli Wu et al. Acta Pharmaceutica Sinica B
- Small-Molecule Modulators Targeting SHP2 for Cancer Therapy
- (2022) Yihua Chen et al. Anti-Cancer Agents in Medicinal Chemistry
- A comprehensive review of BET-targeting PROTACs for cancer therapy
- (2022) Xiao-Li Zhou et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Zinc-dependent deacetylases (HDACs) as potential targets for treating Alzheimer’s disease
- (2022) Yan Li et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Sunitinib-based Proteolysis Targeting Chimeras (PROTACs) reduced the protein levels of FLT-3 and c-KIT in leukemia cell lines
- (2022) Jiadai Zhai et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma
- (2022) Shazia Nakhoda et al. BRITISH JOURNAL OF HAEMATOLOGY
- BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes
- (2022) Li Ma et al. CANCER BIOLOGY & THERAPY
- PROTACting the kinome with covalent warheads
- (2022) Deep Rohan Chatterjee et al. DRUG DISCOVERY TODAY
- Hedysarum Polysaccharide Alleviates Oxidative Stress to Protect Against Diabetic Peripheral Neuropathy via Modulation of the Keap1/Nrf2 signaling pathway
- (2022) Liu He et al. JOURNAL OF CHEMICAL NEUROANATOMY
- Design, synthesis and biological evaluation of novel diarylpyridine derivatives as tubulin polymerisation inhibitors
- (2022) Shanbo Yang et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Synthesis and discovery of the first potent proteolysis targeting chimaera (PROTAC) degrader of AIMP2-DX2 as a lung cancer drug
- (2022) BoRa Lee et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Targeted Protein Degradation by Electrophilic PROTACs that Stereoselectively and Site-Specifically Engage DCAF1
- (2022) Yongfeng Tao et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- An MDM2 degrader for treatment of acute leukemias
- (2022) Bridget K. Marcellino et al. LEUKEMIA
- KEAP1‐NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential
- (2022) Enrique Crisman et al. MEDICINAL RESEARCH REVIEWS
- LRRK2 PROTAC Degraders as a Potential Novel Targeting Strategy for Parkinson's Disease?
- (2022) Alexander Zimprich MOVEMENT DISORDERS
- Targeting androgen receptor phase separation to overcome antiandrogen resistance
- (2022) Jingjing Xie et al. Nature Chemical Biology
- Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
- (2022) Jill Hallin et al. NATURE MEDICINE
- A PROTAC for ALL
- (2022) M. Teresa Villanueva NATURE REVIEWS DRUG DISCOVERY
- Developing antibody-based PROTACs
- (2022) Sarah Crunkhorn NATURE REVIEWS DRUG DISCOVERY
- PROTAC-DB 2.0: an updated database of PROTACs
- (2022) Gaoqi Weng et al. NUCLEIC ACIDS RESEARCH
- A cryptic transactivation domain of EZH2 binds AR and AR’s splice variant, promoting oncogene activation and tumorous transformation
- (2022) Jun Wang et al. NUCLEIC ACIDS RESEARCH
- Selective PARP1 Inhibitors, PARP1-based Dual-Target Inhibitors, PROTAC PARP1 Degraders, and Prodrugs of PARP1 Inhibitors for Cancer Therapy
- (2022) Xiaopeng Peng et al. PHARMACOLOGICAL RESEARCH
- Single-cell transcriptomics identifies Keap1-Nrf2 regulated collective invasion in a Drosophila tumor model
- (2022) Deeptiman Chatterjee et al. eLife
- PROTACs in Gastrointestinal Cancers
- (2022) Yu Chen et al. Molecular Therapy-Oncolytics
- Harnessing the cyclization strategy for new drug discovery
- (2022) Kai Tang et al. Acta Pharmaceutica Sinica B
- Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis
- (2022) Neeta Garg et al. Journal of Clinical Medicine
- The E3 Ligases in Cervical Cancer and Endometrial Cancer
- (2022) Fengguang Zhai et al. Cancers
- Recent Advances of Degradation Technologies Based on PROTAC Mechanism
- (2022) Mingchao Xiao et al. Biomolecules
- Discovery of JAK2/3 Inhibitors from Quinoxalinone-Containing Compounds
- (2022) Kamonpan Sanachai et al. ACS Omega
- PROTAC vaccine: A new way to live attenuated vaccines
- (2022) Zhen Li et al. Clinical and Translational Medicine
- Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models
- (2022) Ye Seul Lim et al. Blood Advances
- Targeting small heat shock proteins to degrade aggregates as a potential strategy in neurodegenerative diseases
- (2022) Tong Lei et al. AGEING RESEARCH REVIEWS
- Identification and structural basis of C-terminal cyclic imides as natural degrons for cereblon
- (2022) Christopher Heim et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer
- (2022) Ge Li et al. BIOCHEMICAL PHARMACOLOGY
- Targeting androgen receptor degradation with PROTACs from bench to bedside
- (2022) Xiaojuan Jia et al. BIOMEDICINE & PHARMACOTHERAPY
- Discovery of selective platelet-derived growth factor receptor-beta (PDGFR-β) bifunctional small-molecule degraders
- (2022) Ru Si et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Design, synthesis, and biological evaluation of BRD4 degraders
- (2022) Mengyuan Ding et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor
- (2022) Jun-ya Kato et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design, synthesis, and biological evaluation of novel protopanoxadiol derivatives based PROTACs technology for the treatment of lung cancer
- (2022) Peng Wang et al. BIOORGANIC CHEMISTRY
- Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis
- (2022) Arunima Jaiswal et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Ubiquitin proteasome system in immune regulation and therapeutics
- (2022) Sameer Ahmed Bhat et al. CURRENT OPINION IN PHARMACOLOGY
- PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery
- (2022) Nicolas Guedeney et al. DRUG DISCOVERY TODAY
- Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs)
- (2022) Aishwarya L. Saraswat et al. DRUG DISCOVERY TODAY
- Design and characterization of PROTAC degraders specific to protein N-terminal methyltransferase 1
- (2022) Qilong Zhou et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers
- (2022) Mingxing Hu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design, synthesis, and biological evaluation of Wee1 kinase degraders
- (2022) Shulei Zhu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- PROTACS: A technology with a gold rush-like atmosphere
- (2022) Yu-Wei Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Dual degradation mechanism of GPX4 degrader in induction of ferroptosis exerting anti-resistant tumor effect
- (2022) Chao Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Briarane-type diterpenoids, the inhibitors of osteoclast formation by interrupting Keap1-Nrf2 interaction and activating Nrf2 pathway
- (2022) Xinyi Qi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Development of potent and selective degraders of PI5P4Kγ
- (2022) Wenzhi Ji et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma
- (2022) Muhammad Rishfi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of pan-IAP degraders via a CRBN recruiting mechanism
- (2022) Seulki Park et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- A bibliometric analysis of PROTAC from 2001 to 2021
- (2022) Deping Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design and optimization of oestrogen receptor PROTACs based on 4-hydroxytamoxifen
- (2022) Guillem Loren et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Modulation of FLT3-ITD and CDK9 in acute myeloid leukaemia cells by novel proteolysis targeting chimera (PROTAC)
- (2022) Eva Řezníčková et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor
- (2022) Haixia Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of novel VEGFR-2-PROTAC degraders based on the localization of lysine residues via recruiting VHL for the treatment of gastric cancer
- (2022) Xing-Rong Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor Cereblon (CRBN): Investigation of their binding mode and antiproliferative effects against myeloma cell lines
- (2022) Mikhail Krasavin et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- miR-495-3p sensitizes BCR-ABL1-expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance 1 gene in T315I mutated cells
- (2022) Yutthana Rittavee et al. EXPERIMENTAL HEMATOLOGY
- Targeting NRF2–KEAP1 axis by Omega-3 fatty acids and their derivatives: Emerging opportunities against aging and diseases
- (2022) Sergio Davinelli et al. FREE RADICAL BIOLOGY AND MEDICINE
- Exploiting ELIOT for Scaffold-Repurposing Opportunities: TRIM33 a Possible Novel E3 Ligase to Expand the Toolbox for PROTAC Design
- (2022) Tommaso Palomba et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeted Protein Degradation Induced by HEMTACs Based on HSP90
- (2022) Zhenzhen Li et al. Journal of Medicinal Chemistry
- Discovery of the First Lactate Dehydrogenase Proteolysis Targeting Chimera Degrader for the Treatment of Pancreatic Cancer
- (2022) Ning Sun et al. Journal of Medicinal Chemistry
- A Comprehensive Overview of Small-Molecule Androgen Receptor Degraders: Recent Progress and Future Perspectives
- (2022) Si Ha et al. Journal of Medicinal Chemistry
- Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity
- (2022) Laura Sinatra et al. Journal of Medicinal Chemistry
- Making Protein Degradation Visible: Discovery of Theranostic PROTACs for Detecting and Degrading NAMPT
- (2022) Junfei Cheng et al. Journal of Medicinal Chemistry
- A Versatile and Sustainable Multicomponent Platform for the Synthesis of Protein Degraders: Proof-of-Concept Application to BRD4-Degrading PROTACs
- (2022) Irene Preet Bhela et al. Journal of Medicinal Chemistry
- Blocking Non-enzymatic Functions by PROTAC-Mediated Targeted Protein Degradation
- (2022) Donghuan Sun et al. Journal of Medicinal Chemistry
- Development of SOS1 Inhibitor-Based Degraders to Target KRAS-Mutant Colorectal Cancer
- (2022) Yujia Bian et al. Journal of Medicinal Chemistry
- Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors
- (2022) Chunrong Yang et al. Journal of the American Chemical Society
- Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets
- (2022) Yan Xiong et al. Journal of the American Chemical Society
- Taurine attenuated methotrexate-induced intestinal injury by regulating NF-κB/iNOS and Keap1/Nrf2/HO-1 signals
- (2022) Emad H.M. Hassanein et al. LIFE SCIENCES
- Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAFV600E Protein
- (2022) Elisabetta Marini et al. MOLECULES
- Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
- (2022) Rui Li et al. MOLECULES
- Current Challenges in Small Molecule Proximity-Inducing Compound Development for Targeted Protein Degradation Using the Ubiquitin Proteasomal System
- (2022) Sridhar Radhakrishnan et al. MOLECULES
- Advancing targeted protein degradation for metabolic diseases therapy
- (2022) Qian-Qian Zhou et al. PHARMACOLOGICAL RESEARCH
- Newly Developed Targeted Therapies Against Androgen Receptor in Triple-Negative Breast Cancer: A Review
- (2022) Edris Choupani et al. PHARMACOLOGICAL REVIEWS
- PROTAC: targeted drug strategy. Principles and limitations
- (2022) O. A. Koroleva et al. RUSSIAN CHEMICAL BULLETIN
- High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells
- (2022) Meng-Yuan Dai et al. Cell Death & Disease
- Potent PROTACs Targeting EGFR Mutants in Drug Discovery
- (2022) Robert B. Kargbo ACS Medicinal Chemistry Letters
- Discovery of Potent PROTACs for the Potential Treatment of Leukemia
- (2022) Robert B. Kargbo ACS Medicinal Chemistry Letters
- Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
- (2022) Jennifer Cantley et al. Nature Communications
- DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
- (2022) Fenglei Li et al. Nature Communications
- Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
- (2022) Samantha B. Kemp et al. Cancer Discovery
- VHL-recruiting PROTAC attenuates renal fibrosis and preserves renal function via simultaneous degradation of Smad3 and stabilization of HIF-2α
- (2022) Jiayi Yang et al. Cell and Bioscience
- E3 ubiquitin ligases in the acute leukemic signaling pathways
- (2022) Qianru Zhan et al. Frontiers in Physiology
- The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma
- (2022) Si-Qi Jia et al. Journal of Immunology Research
- An instructive attempt on developing aptamer-constructed PROTAC for breast cancer treatment
- (2022) Yuzhu Zhang et al. Molecular Therapy-Nucleic Acids
- Design and characterization of a heterobifunctional degrader of KEAP1
- (2022) Hao Chen et al. Redox Biology
- Hypoxia deactivates epigenetic feedbacks via enzyme-derived clicking proteolysis-targeting chimeras
- (2022) Thang Cong Do et al. Science Advances
- Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma
- (2022) Raymond S. Traweek et al. Frontiers in Oncology
- The role of IL-6/JAK2/STAT3 signaling pathway in cancers
- (2022) Bei Huang et al. Frontiers in Oncology
- Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review
- (2022) Jing Shen et al. Frontiers in Oncology
- Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase
- (2022) Anastasia A. Sachkova et al. Pharmaceutics
- Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
- (2022) Arvind Negi et al. Pharmaceutics
- Anticancer Drug Conjugates Incorporating Estrogen Receptor Ligands
- (2022) Darius P. Zlotos et al. Pharmaceutics
- Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer
- (2022) Jinmei Jin et al. JCI Insight
- A Perspective on Newly Emerging Proteolysis-Targeting Strategies in Antimicrobial Drug Discovery
- (2022) Janarthanan Venkatesan et al. Antibiotics-Basel
- PROTAC Degraders of Androgen Receptor‐Integrated Dissolving Microneedles for Androgenetic Alopecia and Recrudescence Treatment via Single Topical Administration
- (2022) Ruxuan Wang et al. Small Methods
- Therapeutic Strategies to Activate p53
- (2022) Angelo Aguilar et al. Pharmaceuticals
- Strategies to Design Selective Histone Deacetylase Inhibitors
- (2021) Wolfgang Sippl et al. ChemMedChem
- Physiological function of FKBP12, a primary target of rapamycin/FK506: a newly identified role in transcription of ribosomal protein genes in yeast
- (2021) Koji Kasahara CURRENT GENETICS
- The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer
- (2021) Theresa E. Hickey et al. NATURE MEDICINE
- Structure-Based Discovery of SIAIS001 as an Oral Bioavailability ALK Degrader Constructed from Alectinib
- (2021) Chaowei Ren et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems
- (2021) Xiaojuan Qu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy
- (2021) Liguo Wang et al. Nature Chemical Biology
- Mutant-selective degradation by BRAF-targeting PROTACs
- (2021) Shanique Alabi et al. Nature Communications
- Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer
- (2021) Linrong Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Bispecific Estrogen Receptor α Degraders Incorporating Novel Binders Identified Using DNA-Encoded Chemical Library Screening
- (2021) Jeremy S. Disch et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery
- (2021) Junping Pei et al. JOURNAL OF MEDICINAL CHEMISTRY
- DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras
- (2021) Xiaoyu Zhang et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog–Thalidomide PROTACs
- (2021) Ga Yeong Kim et al. MOLECULES
- Direct Keap1-kelch inhibitors as potential drug candidates for oxidative stress-orchestrated diseases: A review on In silico perspective
- (2021) Ibrahim Damilare Boyenle et al. PHARMACOLOGICAL RESEARCH
- SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression
- (2021) Haibin Zhou et al. ACS Medicinal Chemistry Letters
- RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases
- (2021) Hajime Honjo et al. Frontiers in Pharmacology
- PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
- (2021) Si-Min Qi et al. Frontiers in Pharmacology
- Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
- (2021) Zhenyi Hu et al. CHEMBIOCHEM
- Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries
- (2021) Bo Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Von Hippel–Lindau (VHL) small-molecule inhibitor binding increases stability and intracellular levels of VHL protein
- (2021) Julianty Frost et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Protein degradation technology: a strategic paradigm shift in drug discovery
- (2021) Haobin Li et al. Journal of Hematology & Oncology
- Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL
- (2021) Liqiang Fu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
- (2021) Weiguo Xiang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)
- (2021) Shaowen Xie et al. JOURNAL OF MEDICINAL CHEMISTRY
- Molecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery
- (2021) Guoqiang Dong et al. JOURNAL OF MEDICINAL CHEMISTRY
- Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer
- (2021) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators
- (2021) Gisele Nishiguchi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Optimization of a Series of RIPK2 PROTACs
- (2021) Afjal H. Miah et al. JOURNAL OF MEDICINAL CHEMISTRY
- Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation
- (2021) Jinyun Dong et al. JOURNAL OF MEDICINAL CHEMISTRY
- Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation
- (2021) Jieli Wei et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Rational Control of Molecular Properties Is Mandatory to Exploit the Potential of PROTACs as Oral Drugs
- (2021) Giuseppe Ermondi et al. ACS Medicinal Chemistry Letters
- E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points
- (2021) Aleša Bricelj et al. Frontiers in Chemistry
- Targeting Protein Kinases Degradation by PROTACs
- (2021) Fei Yu et al. Frontiers in Chemistry
- Commentary: PROTACs make undruggable targets druggable: Challenge and opportunity
- (2021) Bin Lu et al. Acta Pharmaceutica Sinica B
- From the Evasion of Degradation to Ubiquitin-Dependent Protein Stabilization
- (2021) Yamen Abu Ahmad et al. Cells
- Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?
- (2021) Margherita Ambrosini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives
- (2021) Chao Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation
- (2021) Haixia Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Developments of CRBN-based PROTACs as potential therapeutic agents
- (2021) Chao Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Ligands for cereblon: 2017–2021 patent overview
- (2021) Alexander Kazantsev et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- PROTAC cell permeability and oral bioavailability: a journey into uncharted territory
- (2021) Vasanthanathan Poongavanam et al. Future Medicinal Chemistry
- Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders
- (2021) Xufen Yu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor
- (2021) Xiaolun Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Development of BromoTag: A “Bump-and-Hole”–PROTAC System to Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins
- (2021) Adam G. Bond et al. JOURNAL OF MEDICINAL CHEMISTRY
- Diverse alterations associated with resistance to KRAS(G12C) inhibition
- (2021) Yulei Zhao et al. NATURE
- The PROTAC gold rush
- (2021) Ken Garber NATURE BIOTECHNOLOGY
- Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
- (2020) George M. Burslem et al. CELL
- Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)
- (2020) Hao Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma
- (2020) Yun Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders
- (2020) Meng Cheng et al. JOURNAL OF MEDICINAL CHEMISTRY
- PROTACs: A novel strategy for cancer therapy
- (2020) Jing Liu et al. SEMINARS IN CANCER BIOLOGY
- Androgen receptor-binding sites are highly mutated in prostate cancer
- (2020) Tunç Morova et al. Nature Communications
- Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment
- (2020) Steven Kregel et al. NEOPLASIA
- Two-Stage Strategy for Development of Proteolysis Targeting Chimeras and its Application for Estrogen Receptor Degraders
- (2020) Brett L. Roberts et al. ACS Chemical Biology
- Development of CDK2 and CDK5 Dual Degrader TMX‐2172
- (2020) Nathanael Schiander Gray et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Recent Advances in the Design and Development of anticancer molecules based on PROTAC technology
- (2020) Zere Mukhamejanova et al. CURRENT MEDICINAL CHEMISTRY
- Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity
- (2020) Xuan Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design and synthesis of selective degraders of EGFRL858R/T790M mutant
- (2020) Xin Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Small-molecule PROTACs: novel agents for cancer therapy
- (2020) Yichao Wan et al. Future Medicinal Chemistry
- The Role of Bcl-xL Protein Research in Veterinary Oncology
- (2020) Aleksandra Pawlak et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
- (2020) Xin Li et al. Journal of Hematology & Oncology
- Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein
- (2020) Mingliang Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting apoptosis in cancer therapy
- (2020) Benedito A. Carneiro et al. Nature Reviews Clinical Oncology
- PROTAC Technology: Opportunities and Challenges
- (2020) Hongying Gao et al. ACS Medicinal Chemistry Letters
- Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase
- (2020) Ka Yang et al. ACS Medicinal Chemistry Letters
- A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL
- (2020) Bingqi Tong et al. ACS Chemical Biology
- Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines
- (2020) Xuan Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
- (2020) Yonghan He et al. Journal of Hematology & Oncology
- Systematic Investigation of the Permeability of Androgen Receptor PROTACs
- (2020) Duncan E. Scott et al. ACS Medicinal Chemistry Letters
- Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
- (2020) Michael J. Bond et al. ACS Central Science
- Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs
- (2020) Minoru Ishikawa et al. Pharmaceuticals
- First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo
- (2020) Mingming Wei et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Bardoxolone conjugation enables targeted protein degradation of BRD4
- (2020) Bingqi Tong et al. Scientific Reports
- The Natural Compound Notopterol Binds and Targets JAK2/3 to Ameliorate Inflammation and Arthritis
- (2020) Qiong Wang et al. Cell Reports
- A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo
- (2020) Lijie Zhao et al. NEOPLASIA
- Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras
- (2020) Akshay D. Takwale et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of potent small molecule PROTACs targeting mutant EGFR
- (2020) Hong-Yi Zhao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders
- (2020) Jianping Hu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes
- (2020) James Schiemer et al. Nature Chemical Biology
- Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer
- (2020) Shipeng He et al. Acta Pharmaceutica Sinica B
- The PROTAC technology in drug development
- (2019) Yutian Zou et al. CELL BIOCHEMISTRY AND FUNCTION
- A novel cereblon modulator for targeted protein degradation
- (2019) Sung Ah Kim et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)
- (2019) Jiantao Hu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Developing potent PROTACs tools for selective degradation of HDAC6 protein
- (2019) Zixuan An et al. Protein & Cell
- ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
- (2019) Taavi Neklesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs
- (2019) Miriam Girardini et al. BIOORGANIC & MEDICINAL CHEMISTRY
- PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding
- (2019) Christopher P. Tinworth et al. ACS Chemical Biology
- Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications
- (2019) Carl C. Ward et al. ACS Chemical Biology
- Structure–Activity and Structure–Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1/NRF2) Protein–Protein Interaction
- (2019) Tom D. Heightman et al. JOURNAL OF MEDICINAL CHEMISTRY
- Treatment of Prostate Cancers and Kennedy’s Disease by PROTAC-Androgen Receptor Degradation
- (2019) Robert B. Kargbo ACS Medicinal Chemistry Letters
- Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: Recent progress and future challenges
- (2019) Scott D. Edmondson et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Targeted protein degradation: elements of PROTAC design
- (2019) Stacey-Lynn Paiva et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives
- (2019) Christopher Heim et al. JOURNAL OF MEDICINAL CHEMISTRY
- Harnessing the anti-cancer natural product nimbolide for targeted protein degradation
- (2019) Jessica N. Spradlin et al. Nature Chemical Biology
- Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
- (2019) Xiaoyu Zhang et al. Nature Chemical Biology
- Targeting IRAK4 for Degradation with PROTACs
- (2019) Joao Nunes et al. ACS Medicinal Chemistry Letters
- Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations
- (2019) Mélissanne de Wispelaere et al. Nature Communications
- RNF4 – A Paradigm for SUMOylation‐Mediated Ubiquitination
- (2019) Ramesh Kumar et al. PROTEOMICS
- Degradation of proteins by PROTACs and other strategies
- (2019) Yang Wang et al. Acta Pharmaceutica Sinica B
- Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins
- (2019) Nobumichi Ohoka et al. ACS Chemical Biology
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
- (2019) Longchuan Bai et al. CANCER CELL
- Novel activators and small-molecule inhibitors of STAT3 in cancer
- (2019) Lehe Yang et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)
- (2019) Peter S. Dragovich et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein
- (2019) Haibin Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design, synthesis, and biological evaluation of small molecule PROTACs for potential anticancer effects
- (2019) Yang Da et al. MEDICINAL CHEMISTRY RESEARCH
- A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
- (2019) Sajid Khan et al. NATURE MEDICINE
- Direct Targeting Options for STAT3 and STAT5 in Cancer
- (2019) Anna Orlova et al. Cancers
- Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2
- (2018) Meidan Ying et al. BLOOD
- Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer
- (2018) Ryohei Katayama CANCER SCIENCE
- Chemical Protein Degradation Approach and its Application to Epigenetic Targets
- (2018) Yukihiro Itoh CHEMICAL RECORD
- Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway
- (2018) Mengchen Lu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)
- (2018) Chelsea E. Powell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
- (2018) Chong Qin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
- (2018) Voon Yee-Lin et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Homo-PROTACs for the Chemical Knockdown of Cereblon
- (2018) Christian Steinebach et al. ACS Chemical Biology
- Structural basis for drug resistance mechanisms against anaplastic lymphoma kinase
- (2018) Sukriti Goyal et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
- (2018) Sainan An et al. EBioMedicine
- MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
- (2018) John Hines et al. CANCER RESEARCH
- Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
- (2018) Solomon Tadesse et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression
- (2018) Yangbing Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Histone Deacetylase Inhibitors as Anticancer Drugs
- (2017) Tomas Eckschlager et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Discovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP)
- (2017) Emiliano Tamanini et al. JOURNAL OF MEDICINAL CHEMISTRY
- Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase: Structure–Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298)
- (2017) Pedro Soares et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1
- (2017) Andrew P. Crew et al. JOURNAL OF MEDICINAL CHEMISTRY
- Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands
- (2017) Norihito Shibata et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structural basis of PROTAC cooperative recognition for selective protein degradation
- (2017) Morgan S Gadd et al. Nature Chemical Biology
- Bladder cancer: Benefit of adjuvant chemotherapy in UTUC unclear
- (2017) Clemens Thoma Nature Reviews Urology
- Targeted protein degradation by PROTACs
- (2017) Taavi K. Neklesa et al. PHARMACOLOGY & THERAPEUTICS
- Cellular retinoid binding-proteins, CRBP, CRABP, FABP5: Effects on retinoid metabolism, function and related diseases
- (2017) Joseph L. Napoli PHARMACOLOGY & THERAPEUTICS
- p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates
- (2017) Thang Van Nguyen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
- (2017) Ting Han et al. SCIENCE
- Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation
- (2017) Chiara Maniaci et al. Nature Communications
- Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand
- (2016) Yosuke Demizu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
- (2016) Priyanka A. Pophali et al. CANCER JOURNAL
- Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
- (2016) Nobumichi Ohoka et al. CURRENT CANCER DRUG TARGETS
- Targeted Degradation of Proteins Localized in Subcellular Compartments by Hybrid Small Molecules
- (2016) Keiichiro Okuhira et al. MOLECULAR PHARMACOLOGY
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
- (2016) Jonathan M. L. Ostrem et al. NATURE REVIEWS DRUG DISCOVERY
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition
- (2016) Julianty Frost et al. Nature Communications
- Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL
- (2015) Ashton C. Lai et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Regulation of RAF protein kinases in ERK signalling
- (2015) Hugo Lavoie et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel
- (2015) Zhen Ning Wee et al. Nature Communications
- The TLR and IL-1 signalling network at a glance
- (2014) P. Cohen JOURNAL OF CELL SCIENCE
- Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities
- (2014) Carles Galdeano et al. JOURNAL OF MEDICINAL CHEMISTRY
- Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment
- (2014) Yujun Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- IRAK4 Dimerization and trans -Autophosphorylation Are Induced by Myddosome Assembly
- (2014) Ryan Ferrao et al. MOLECULAR CELL
- Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
- (2014) Eric S. Fischer et al. NATURE
- Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation
- (2014) Neroshan Thevakumaran et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs
- (2014) Philip P Chamberlain et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Targeting p53 for Novel Anticancer Therapy
- (2014) Zhen Wang et al. Translational Oncology
- ZNF313 is a novel cell cycle activator with an E3 ligase activity inhibiting cellular senescence by destabilizing p21WAF1
- (2013) J Han et al. CELL DEATH AND DIFFERENTIATION
- Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
- (2013) Qingjie Ding et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development
- (2013) Binh Vu et al. ACS Medicinal Chemistry Letters
- Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction
- (2012) Dennis L. Buckley et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Implementation of a High-Throughput Screen for Identifying Small Molecules to Activate the Keap1-Nrf2-ARE Pathway
- (2012) Kai Connie Wu et al. PLoS One
- Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells
- (2012) Konstantin V. Golovine et al. PROSTATE
- Development of target protein-selective degradation inducer for protein knockdown
- (2011) Yukihiro Itoh et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Teratogenic effects of thalidomide: molecular mechanisms
- (2011) Takumi Ito et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- The Mechanism of Thalidomide Deformities Correlated with the Pathogenic Effects of Prolonged Dosage in Adults
- (2010) Gavin Gordon DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY
- Protein Knockdown Using Methyl Bestatin−Ligand Hybrid Molecules: Design and Synthesis of Inducers of Ubiquitination-Mediated Degradation of Cellular Retinoic Acid-Binding Proteins
- (2010) Yukihiro Itoh et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Helical assembly in the MyD88–IRAK4–IRAK2 complex in TLR/IL-1R signalling
- (2010) Su-Chang Lin et al. NATURE
- Cellular Retinoic Acid-binding Protein II: A Coactivator of the Transactivation by the Retinoic Acid Receptor Complex RAR.RXR
- (2010) George Wolf NUTRITION REVIEWS
- Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line
- (2009) Gemma Marcias et al. HUMAN MUTATION
- Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
- (2009) H Quach et al. LEUKEMIA
- The ubiquitin system
- (2009) Deepa Nath et al. NATURE
- Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy
- (2008) Sanjeev Shangary et al. Annual Review of Pharmacology and Toxicology
- Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics
- (2008) Ashley R. Schneekloth et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Targeting the MDM2-p53 Interaction for Cancer Therapy
- (2008) S. Shangary et al. CLINICAL CANCER RESEARCH
- The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies
- (2008) Paola Secchiero et al. CURRENT PHARMACEUTICAL DESIGN
- Substrate-Assisted Catalysis by PARP10 Limits Its Activity to Mono-ADP-Ribosylation
- (2008) Henning Kleine et al. MOLECULAR CELL
- Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer
- (2008) A Rodriguez-Gonzalez et al. ONCOGENE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started